Intelligent Observation.
Better Care.

For Clinical Trials for population health
Main Model

At AiCure, every dose matters.

Failed trials & overwhelming healthcare costs

30% of clinical trials fail and millions of
high-risk patients are hospitalized each year
due to poor medication adherence.

Invisible patient behavior

90% of patient behavior remains unknown
in outpatient settings.

A visual journey with the patient

AiCure accurately captures, analyzes
and impacts behavior through
artificial intelligence.

The new gold standard

Pharmaceutical companies and health
systems are using AiCure to drive successful
trials and improve health outcomes.

How the AI platform works

Our Artificial Intelligence platform

HIPAA-compliant facial
recognition

Automatic medication
identification

Real-time ingestion
confirmation

Fraud and duplicate
enrollment detection

No video review
is needed

Download application
onto any smartphone

Analytics allow for
pre-emptive intervention

Assistive technology for
greater patient engagement

Testimonials

AiCure has developed a remarkable artificial intelligence application.

CHRISTOPHER P. AUSTIN, M.D.
Director, National Center for Advancing Translational Sciences, NIH

Applying AiCure’s artificial intelligence to healthcare has the potential to impact millions of lives on a global scale.

DR. BORIS NIKOLIC, M.D.
Former Chief Scientific Advisor to Bill Gates

The AiCure platform may help our ability to detect a drug's effectiveness and help us reduce costs by decreasing the number of patients needed in studies.

ATUL R. MAHABLESHWARKAR, M.D.
Senior Medical Director, Takeda

Clinical Evidence

%

Increase in Drug Concentration Levels

in stroke patients on DOACs
post-discharge1

%

Mean Cumulative Pharmacokinetic Adherence

over 24 weeks across indications2

%

Treatment Completion Rates

in patients with hepatitis C and tuberculosis3

As seen on

  1. Labovitz, et al. Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy. Stroke. 2017 May.
  2. Bain EE, et al. Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects with Schizophrenia. JMIR Mhealth Uhealth. 2017 Feb 21;5(2):e18
  3. Shafner L, et al. Evaluating the Use of an Artificial Intelligence (AI) Platform on Mobile Devices to Measure and Support Tuberculosis Medication Adherence. Presented during the 21st Conference of The Union North America Region, 22-25 February, 2017. 6Chuang-Stein C, et al. The Impact of Adherence on Statistical Power. 2016. AiCure.

Complete the form below to download

Fields marked with * are mandatory

+

Contact AiCure to learn more

Fields marked with * are mandatory








+